April 3, 2025 07:11 AM EDTUpdated 07:39 AM
R&D

Sarep­ta, Roche pause Ele­v­idys tri­als in Eu­rope fol­low­ing pa­tient death

Ayisha Sharma

News Reporter

Sarep­ta and Roche are hit­ting the brakes on three tri­als of their Duchenne gene ther­a­py Ele­v­idys in re­sponse to a re­quest by the Eu­ro­pean Med­i­cines …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

The in­side sto­ry of how Sali­o­Gen, a start­up try­ing to wran­gle ‘jump­ing genes’ to make med­i­cines, fell apart

Miss­ing REMS de­lays Cy­to­ki­net­ic­s' heart drug PDU­FA, stock drops

For­mer Tome CEO joins Flag­ship start­up; NGM Bio chief steps down as re­struc­tur­ing takes ef­fect

RFK Jr. claims place­bo-con­trolled vac­cine tri­als are 'rad­i­cal de­par­ture' from past. Ex­perts dis­agree

In­vestors un­veil plans for $1.3B can­cer hub in Lon­don sub­urbs

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times